Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joshua Maddox

Orthopaedic Surgery Enterprise, AL Doctor of Osteopathy

NPI 1083155113 CMS profile 4218080

404 N Main St, Enterprise, AL 36330

Open in the dashboard

General payments

$14,616

108 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joshua Maddox of Enterprise, AL is reported in the CMS Open Payments database as having received $14,616 across 108 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $819 26
2024 General $125 6
2023 General $1,631 25
2022 General $9,887 47
2021 General $1,208 2
2019 General $945 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joshua Maddox
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Joshua Maddox were reported at $819. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Joshua Maddox Orthopaedic Surgery median Middle half National median
2019 $945 $644 $140–$2,844 $163
2020 $0 $312 $75–$1,860 $114
2021 $1,208 $520 $117–$2,495 $132
2022 $9,887 $598 $128–$2,731 $149
2023 $1,631 $461 $128–$2,264 $160
2024 $125 $497 $134–$2,475 $164
2025 $819 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. NuVasive, Inc. $8,189 52 payments
  2. Medtronic, Inc. $2,938 14 payments
  3. Pinnacle, Inc $2,153 4 payments
  4. Globus Medical, Inc. $834 20 payments
  5. Djo, LLC $168 8 payments
  6. Stryker Corporation $104 1 payment
  7. Carlsmed, Inc. $73 1 payment
  8. Ethicon US, LLC $66 1 payment
  9. Orthofix Medical, Inc. $59 5 payments
  10. Pacira Pharmaceuticals Incorporated $22 1 payment
  11. Other $8 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $9,720 31 payments
  2. Food and Beverage $2,757 75 payments
  3. Education $2,139 2 payments
Products named General payments · program years 2019–2025
  1. XLIF $3,616 26 payments
  2. Pulse $3,347 14 payments
  3. TLIF $1,415 16 payments
  4. ALIF $275 4 payments
  5. CMF $168 8 payments
  6. MAZOR X SYSTEM $137 1 payment
  7. T2 $104 1 payment
  8. Excelsius Robotics System $97 1 payment
  9. aprevo $73 1 payment
  10. DERMABOND PRINEO $66 1 payment
  11. Other $817 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

1,166

Median for Orthopedic Surgery: 203

Drug cost

$8,942

Median for Orthopedic Surgery: $1,433

Branded share of claims

26.8%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 261 $2,211
Methylprednisolone Generic 175 $1,452
Celecoxib Generic 78 $1,222
Ondansetron Hcl Generic 110 $1,013
Diclofenac Sodium Generic 59 $639
Tramadol Hcl Generic 174 $587
Gabapentin Generic 87 $427
Cyclobenzaprine Hcl Generic 57 $409
Methocarbamol Generic 31 $388
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 23 $256

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 90 billing codes

Paid by Medicare

$101,695

Of which drugs: $3,026

Medicare patients

264

Average age 73

Services billed

1,120

153 women, 111 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 34%
Ischemic heart disease 27%
Chronic kidney disease 27%
Depression 27%
COPD 20%
Heart failure 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 47 87 $459

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

108 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record